Tenofovir-associated severe bone pain: I cannot walk!

Journal of the International Association of Physicians in AIDS Care

Volumn 9, Issue 5, 2010, Pages 328-334

  Jhaveri, Malhar A ^a   Mawad, Hanna W ^b   Thornton, Alice C ^b   Mullen, Nancy W ^c   Greenberg, Richard N ^b,d  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Bluegrass Care Clinic   (United States)

^d LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

AIDS; bone pain; tenofovir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALLOPURINOL; AMFEBUTAMONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; ATAZANAVIR PLUS TENOFOVIR; CALCIFEDIOL; CALCIUM CARBONATE; COLCHICINE; COLECALCIFEROL; DICLOXACILLIN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MORPHINE SULFATE; OXYCODONE; OXYCODONE PLUS PARACETAMOL; PERCOCET; PHOSPHATE; PRAVASTATIN; PROMETHAZINE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BICARBONATE BLOOD LEVEL; BODY MASS; BONE DENSITY; BONE PAIN; CALCIUM BLOOD LEVEL; CASE REPORT; CD4 LYMPHOCYTE COUNT; CELLULITIS; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; GOUT; HEPATITIS C; HUMAN; HUMAN CELL; IMMOBILIZATION; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PHOSPHATE BLOOD LEVEL; POSITRON EMISSION TOMOGRAPHY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; VIRUS LOAD; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; ADENINE; ADULT; ALKALINE PHOSPHATASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BICARBONATES; BONE DENSITY CONSERVATION AGENTS; FANCONI SYNDROME; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOBILITY LIMITATION; OSTEOPOROSIS; PAIN; PHOSPHONIC ACIDS;

EID: 78650802938     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109710376595     Document Type: Article

References (32)

1. US FDA Center for Drug Evaluation and Research. 2001. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails. Accessed October 20, 2009.
2. Meier P., Dautheville-Guibal S., Ronco PM, Rossert J. Cidofovirinduced end-stage renal failure. Nephrol Dial Transplant. 2002 ; 17 (1). 148-149.
3. Tanji N., Tanji K., Kambham N., Markowitz GS, Bell A., D'Agati VD Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001 ; 32 (7). 734-740.
4. Brim NM, Cu-Uvin S., Hu SL, O'Bell JW Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read. 2007 ; 17 (6). 322-328, C3.
5. Earle KE, Seneviratne T., Shaker J., Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res. 2004 ; 19 (5). 714-721.
6. Gaspar G., Monereo A., Garcia-Reyne A., de Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS. 2004 ; 18 (2). 351-352.
7. Mathew G., Knaus SJ Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med. 2006 ; 21 (11). C3 - C5.
8. Perrot S., Aslangul E., Szwebel T., Caillat-Vigneron N., Le Jeunne C. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol. 2009 ; 15 (2). 72-74.
9. Peyriere H., Reynes J., Rouanet I., et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004 ; 35 (3). 269-273.
10. Rifkin BS, Perazella MA Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004 ; 117 (4). 282-284.
11. Bando H., Hashimoto N., Hirota Y., et al. Severe hypophosphatemic osteomalacia with Fanconi syndrome, renal tubular acidosis, vitamin D deficiency and primary biliary cirrhosis. Intern Med. 2 009; 48 (5). 353-358.
12. Parsonage MJ, Wilkins EG, Snowden N., Issa BG, Savage MW The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. 2005 ; 6 (5). 341-346.
13. Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2 009; 10 (8). 482-487.
14. Wever K., van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. Published ahead of print February 2010 (doi:10.1097/QAI.0b013e3181d05579) .
15. Cazanave C., Dupon M., Lavignolle-Aurillac V., et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008 ; 22 (3). 395-402.
16. Brown TT, Qaqish RB Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006 ; 20 (17). 2165-2174.
17. Richards JB, Kavvoura FK, Rivadeneira F., et al. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med. 2 009; 151 (8). 528-537.
18. Cote HC, Magil AB, Harris M., et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther. 2006 ; 11 (1). 79-86.
19. Fux CA, Christen A., Zgraggen S., Mohaupt MG, Furrer H. Effect of tenofovir on renal glomerular and tubular function. AIDS. 2007 ; 21 (11). 1483-1485.
20. Mocroft A., Kirk O., Gatell J., et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007 ; 21 (9). 1119-1127.
21. Kohler JJ, Hosseini SH, Hoying-Brandt A., et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009 ; 89 (5). 513-519.
22. Bianchi V. Nucleotide pool unbalance induced in cultured cells by treatments with different chemicals. Toxicology. 1982 ; 25 (1). 13-18.
23. Rodriguez-Novoa S., Labarga P., Soriano V., et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009 ; 48 (11). e108 - e116.
24. Magen D., Berger L., Coady MJ, et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med. 2010 ; 362 (12). 1102-1109.
25. Bergwitz C., Roslin NM, Tieder M., et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet. 2006 ; 78 (2). 179-192.
26. Lorenz-Depiereux B., Benet-Pages A., Eckstein G., et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet. 2006 ; 78 (2). 193-201.
27. Murer H., Forster I., Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004 ; 447 (5). 763-767.
28. Segawa H., Onitsuka A., Furutani J., et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol. 2009 ; 297 (3). F671 - F678.
29. Rastegar A. New concepts in pathogenesis of renal hypophosphatemic syndromes. Iran J Kidney Dis. 2009 ; 3 (1). 1-6.
30. Moe SM Disorders involving calcium, phosphorus, and magnesium. Prim Care. 2008 ; 35 (2). 215-237v-vi.
31. Reilly BM, Hart PD, Mascarell S., Chatrath H. Clinical problem-solving. A question well put. N Engl J Med. 2009 ; 360 (14). 1446-1451.
32. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001 ; 98 (11). 6500-6505.